| 张雯静,尹建坤,李萌,等.芪术肺纤汤对特发性肺间质纤维化患者血清KL-6水平和肺功能影响的疗效观察[J].浙江中医药大学学报,2023,47(11):1323-1329. |
| 芪术肺纤汤对特发性肺间质纤维化患者血清KL-6水平和肺功能影响的疗效观察 |
| Effect of Qizhu Feixian Decoction on Serum KL-6 Level and Lung Function in Patients with Idiopathic Pulmonary Fibrosis |
| DOI：10.16466/j.issn1005-5509.2023.11.015 |
| 中文关键词: 芪术肺纤汤 特发性肺间质纤维化 KL-6 肺功能 临床疗效 李国勤 |
| 英文关键词: Qizhu Feixian Decoction idiopathic pulmonary fibrosis KL-6 lung function clinical efficacy LI Guoqin |
| 基金项目:国家自然科学基金青年项目(82004347)；中央本级重大增减支项目(2060302) |
|
| 摘要点击次数: 1269 |
| 全文下载次数: 689 |
| 中文摘要: |
| [目的] 探讨芪术肺纤汤对特发性肺间质纤维化(idiopathic pulmonary fibrosis，IPF)患者血清涎液化糖链抗原6(Krebs Von Den Lungen-6，KL-6)水平和肺功能的影响。[方法] 搜集2019年10月1日至2021年12月31日于中国中医科学院广安门医院就诊的IPF患者40例，分为试验组和对照组各20例，对照组口服乙酰半胱氨酸胶囊加百令胶囊，试验组在此基础上加用芪术肺纤汤，3个月后观察两组患者治疗前后肺功能、中医症状积分、血清KL-6水平变化及不良反应。[结果] 与治疗前比较，治疗后试验组最大肺活量占预计值的百分比(vital capacity max/predict value，VCmax%)、一氧化碳弥散量占预计值的百分比(carbon moNOxide diffusing capacity/predict value，DLCO%)及肺总量占预计值的百分比(total lung capacity/predict value，TLC%)均上升，TLC%差异有统计学意义(P<0.05)；对照组TLC%、DLCO%及VCmax%均下降，且VCmax%差异有统计学意义(P<0.01)。治疗后组间比较，试验组VCmax%、TLC%和DLCO%均高于对照组，且DLCO%差异有统计学意义(P<0.01)。与治疗前比较，治疗后两组患者中医症状总积分、主症总积分及次症总积分均较前下降(P<0.01，P<0.05)。其中试验组主症喘息、气短、咳痰积分及次症乏力积分均较前显著下降(P<0.01，P<0.05)，对照组仅主症气短积分显著下降(P<0.05)，余如喘息、咳嗽、咳痰、乏力等症状积分略有下降，差异无统计学意义(P>0.05)。治疗后组间比较，试验组症状总积分、主症总积分、主症喘息、气短、咳嗽积分显著低于对照组，差异具有统计学意义(P<0.01，P<0.05)。与治疗前比较，治疗后试验组血清KL-6水平下降，但差异无统计学意义(P>0.05)；对照组血清KL-6水平上升(P<0.01)。治疗后组间比较，试验组血清KL-6水平明显低于对照组，差异具有统计学意义(P<0.05)。两组患者均无不良反应发生。[结论] 芪术肺纤汤可提高IPF患者肺功能，显著升高DLCO%指标，改善喘息气短、咳痰乏力等症状，并能降低血清KL-6水平，延缓肺纤维化进程，治疗干预期间未见不良反应，安全可靠。 |
| 英文摘要: |
| [Objective] To investigate the effects of Qizhu Feixian Decoction on serum Krebs Von Den Lungen-6(KL-6) level， and lung function in patients with idiopathic pulmonary fibrosis(IPF). [Methods] A total of 40 patients with IPF admitted to the Guang’ anmen Hospital of Chinese Academy of Chinese Medical Sciences from October 1，2019， to December 31，2021 were selected， and the patients were split into 2 ?groups. The control group was treated with Acetylcysteine Capsules and Bailing Capsules， and the trial group was treated with Qizhu Feixian Decoction based on the former. After 3 months of treatment， the lung function， the traditional Chinese medicine(TCM) syndrome scores， serum KL-6 level and adverse reactions were contrasted between the two groups. [Results] After treatment， the vital capacity max/predict value(VCmax%)， carbon moNOxide diffusing capacity/predict value(DLCO%) and total lung capacity/predict value(TLC%) in trial group were significantly higher than those before treatment， the difference in TLC% was statistically significant (P<0.05)， while the TLC%， DLCO% and VCmax% in control group were lower than those before treatment， and VCmax% had significant difference(P<0.01). After treatment， VCmax%， TLC% and DLCO% in the trial group were higher than those in control group， and DLCO% had significant difference(P<0.01). Compared with before treatment， the total scores of TCM symptoms， main symptoms and minor symptoms in both groups decreased(P<0.01， P<0.05). The scores of wheezing， shortness of breath， expectoration and fatigue were remarkably decreased in trial group(P<0.01， P<0.05)， but only the scores of shortness of breath were remarkably decreased in control group(P<0.05)， the scores of other symptoms such as wheezing， cough， expectoration and fatigue decreased slightly(P>0.05). After treatment， the total scores of symptoms， main symptoms， main symptoms of wheezing， shortness of breath and cough in trial group were remarkably lower than those in control group， and the difference was statistically significant(P<0.01， P<0.05). After treatment， the serum KL-6 level in trial group decreased(P>0.05)， while that in control group increased(P<0.01). After treatment， the serum KL-6 level in trial group was dramatically lower than that in control group with statistically significant difference(P<0.05). There were no adverse reactions happening in the two groups. [Conclusion] Qizhu Feixian Decoction can improve lung function， increase DLCO%， improve symptoms such as wheezing shortness of breath， expectoration， and fatigue， decrease the level of serum KL-6， and delay the progress of pulmonary fibrosis， no adverse reactions happened during the treatment， and the effect was safe and reliable. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |